Pasar al contenido principal

NUEVAS APROXIMACIONES EXPERIMENTALES PARA ANALIZAR EL PAPEL DE LA NADPH OXIDASA NOX4 EN REGENERACION Y CANCER HEPATICOS. RELACION CON LA VIA DEL TGF-BETA.

RTI2018-094079-B-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos I+D+i Retos de Investigación
Año convocatoria 2018
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario FUNDACIO INSTITUT D INVESTIGACIO BIOMEDICA DE BELLVITGE (IDIBELL)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

The NADPH oxidase NOX4 regulates redox and metabolic homeostasis preventing HCC progression

  • Peñuelas-Haro, Irene
  • Espinosa-Sotelo, Rut
  • Crosas-Molist, Eva
  • Herranz-Itúrbide, Macarena
  • Caballero-Díaz, Daniel
  • Alay, Ania
  • Solé, Xavier
  • Ramos, Emilio
  • Serrano, Teresa
  • Martínez-Chantar, María Luz
  • Knaus, Ulla G.
  • Cuezva, José M.
  • Zorzano, Antonio
  • Bertran, Esther
  • Fabregat, Isabel
Background and aims: The NADPH oxidase NOX4 plays a tumor-suppressor function in HCC. Silencing NOX4 confers higher proliferative and migratory capacity to HCC cells and increases their in vivo tumorigenic potential in xenografts in mice. NOX4 gene deletions are frequent in HCC, correlating with higher tumor grade and worse recurrence-free and overall survival rates. However, despite the accumulating evidence of a protective regulatory role in HCC, the cellular processes governed by NOX4 are not yet understood. Accordingly, the aim of this work was to better understand the molecular mechanisms regulated by NOX4 in HCC in order to explain its tumor-suppressor action. Approach and results: Experimental models: cell-based loss or gain of NOX4 function experiments, in vivo hepatocarcinogenesis induced by diethylnitrosamine in Nox4-deficient mice, and analyses in human HCC samples. Methods include cellular and molecular biology analyses, proteomics, transcriptomics, and metabolomics, as well as histological and immunohistochemical analyses in tissues. Results identified MYC as being negatively regulated by NOX4. MYC mediated mitochondrial dynamics and a transcriptional program leading to increased oxidative metabolism, enhanced use of both glucose and fatty acids, and an overall higher energetic capacity and ATP level. NOX4 deletion induced a redox imbalance that augmented nuclear factor erythroid 2-related factor 2 (Nrf2) activity and was responsible for MYC up-regulation. Conclusions: Loss of NOX4 in HCC tumor cells induces metabolic reprogramming in a Nrf2/MYC-dependent manner to promote HCC progressio, Supported by Agencia Estatal de Investigación, Ministerio de Ciencia e Innovación, Spain (co‐funded by European Regional Development Fund ERDF, a way to build Europe) (SAF2015‐64149‐R, RTI2018‐094079‐B‐100, PID2021‐122551OB‐I00, PID2019‐106209RB‐I00, PID2019‐108674RB‐100, and RED2018‐102576‐T); FPI fellowships (BES‐2016‐077564 and PRE2019‐089144); the Generalitat de Catalunya (2017SGR1015); Science Foundation Ireland (16/IA/4501); CIBER, National Biomedical Research Institute, which is funded by the Instituto de Salud Carlos III, Spain; CERCA Programme/Generalitat de Catalunya; and an ICREA “Academia” Award (Generalitat de Catalunya)
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

The hepatocyte epidermal growth factor receptor (EGFR) pathway regulates the cellular interactome within the liver fibrotic niche

  • Gonzalez-Sanchez, Ester
  • Vaquero, Javier
  • Caballero-Díaz, Daniel
  • Grzelak, Jan
  • Fusté, Noel P.
  • Bertran, Esther
  • Amengual, Josep
  • Garcia-Saez, Juan
  • Martín-Mur, Beatriz
  • Gut, Marta
  • Esteve-Codina, Anna
  • Alay, Ania
  • Coulouarn, Cédric
  • Calero-Pérez, Silvia
  • Valdecantos, Pilar
  • Valverde, Ángela M.
  • Sánchez, Aranzazu
  • Herrera, Blanca
  • Fabregat, Isabel
Liver fibrosis is the consequence of chronic liver injury in the presence of an inflammatory component. Although the main executors of this activation are known, the mechanisms that lead to the inflammatory process that mediates the production of pro-fibrotic factors are not well characterized. Epidermal growth factor receptor (EGFR) signaling in hepatocytes is essential for the regenerative processes of the liver; however, its potential role in regulating the fibrotic niche is not yet clear. Our group generated a mouse model that expresses an inactive truncated form of the EGFR specifically in hepatocytes (ΔEGFR mice). Here, we have analyzed the response of WT and ΔEGFR mice to chronic treatment with carbon tetrachloride (CCl4), which induces a pro-inflammatory and fibrotic process in the liver. The results indicated that the hallmarks of liver fibrosis were attenuated in CCl4-treated ΔEGFR mice when compared with CCl4-treated WT mice, coinciding with a faster resolution of the fibrotic process and ameliorated damage. The absence of EGFR activity in hepatocytes induced changes in the pattern of immune cells in the liver, with a notable increase in the population of M2 macrophages, more related to fibrosis resolution, as well as in the population of lymphocytes related to eradication of the damage. Transcriptome analysis of hepatocytes, and secretome studies of extracellular media from in vitro experiments, allowed us to elucidate the specific molecular mechanisms regulated by EGFR that mediate hepatocyte production of both pro-fibrotic and pro-inflammatory mediators; these have consequences for the deposition of extracellular matrix proteins, as well as for the immune microenvironment. Overall, our study uncovered novel mechanistic insights regarding EGFR kinase-dependent actions in hepatocytes that reveal its key role in chronic liver damage., This work was supported by (i) Fundacion Ramon Areces 20th National Competition for Scientific and Technical Research in Life and Matter Science 2020, grant # CIVP20A6593, to IF; (ii) Ministerio de Ciencia e Innovación (MICINN), Spain, which is part of the Agencia Estatal de Investigación (AEI), through (a) the Retos Investigación grants, numbers: RTI2018-094079-B-100 (co-funded by European Regional Development Fund, ERDF, a way to build Europe) to IF; PID2021-122551OB-100 funded by MCIN/AEI/10.13039/501100011033/FEDER, UE to IF; RTI2018-099098-B-100 funded by MCIN/AEI/10.13039/501100011033/FEDER, UE to AS/BH; PID-2021-122766OB-100 funded by MCIN/AEI/10.13039/501100011033 to AMV; and (b) the Retos Colaboración grant number RTC2019-007125-1 to IF. JV was funded by MICINN/AEI, through the Retos Investigación grant number PID2019-108651RJ-I00/DOI 10.13039/501100011033 and ‘Ramon y Cajal’ program RYC2021-034121-I. The CIBEREHD, National Biomedical Research Institute on Liver and Gastrointestinal Diseases, is funded by the Instituto de Salud Carlos III, Spain. We thank CERCA Programme/Generalitat de Catalunya for institutional support., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

NADPH oxidase 1/4 dual inhibition impairs transforming growth factor-beta protumorigenic effects in cholangiocarcinoma cancer-associated fibroblasts

  • Amengual, Josep
  • Gonzalez-Sanchez, Ester
  • Yáñez-Bartolome, Mariana
  • Sererols-Viñas, Laura
  • Ravichandran, Sriram
  • Guiton, Celia
  • Fuste, Noel P.
  • Alay, Ania
  • Hijazo-Pechero, Sara
  • Martín-Mur, Beatriz
  • Gut, Marta
  • Esteve-Codina, Anna
  • Cantos-Cortes, Ana
  • Espinosa-Sotelo, Rut
  • Ramos, Emilio
  • Serrano, Teresa
  • Calvo, Mariona
  • Laquente, Berta
  • Ferrer, Joana
  • Pons, Gabriel
  • Mendez-Lucas, Andrés
  • Dooley, Steven
  • Ilyas, Sumera I.
  • Vallette, Marie
  • Aoudjehane, Lynda
  • Lequoy, Marie
  • Fouassier, Laura
  • Coulouarn, Cédric
  • Affò, Silvia
  • Scheiter, Alexander
  • Calvisi, Diego F.
  • Tian, Tian V.
  • Fabregat, Isabel
  • Vaquero, Javier
Transforming growth factor beta (TGF-β) signalling has become an attractive therapeutic target due to its pro-tumorigenic actions on epithelial cells and its immunosuppressive effects in the tumour microenvironment. In intrahepatic cholangiocarcinoma (iCCA), a highly aggressive malignancy of the biliary tract with poor prognosis, the latest clinical trials using TGF-β inhibitors have failed indicating that the specific actions carried out by TGF-β in iCCA are yet not well delineated. Here, we show that TGF-β signalling is highly active in iCCA and exerts a prominent suppressor effect on tumour cell lines and organoids established from iCCA metastases biopsies, that relies on a functional canonical SMAD2/3/4 signalling. Thus, TGF-β inhibitors promote, instead of inhibiting, tumour cell growth. In this context, a promising strategy is to target intracellular proteins downstream the TGF-β receptors accounting only for TGF-β pro-tumorigenic actions. NADPH oxidase 4 (NOX4), a downstream mediator of the TGF-β signalling pathway, is strictly expressed in cancer-associated fibroblasts (CAF) of iCCA and acts in concert with NOX1 to regulate CAF functions. Use of a dual NOX4/NOX1 inhibitor impaired CAF actions and reduced tumour growth in vitro and in two different in vivo iCCA experimental models. Collectively, our findings reveal an actionable way to specifically target TGF-β pro-tumorigenic actions in CAF from iCCA without undesirable side effects on tumour cells, suggesting a potentially bright future for dual NOX4/NOX1 inhibitors in the clinics, alone or in combination with other therapies., This work was supported by (i) Spanish Association for Cancer Research (AECC), Spain, grant #PRYGN211279FABR, to I.F.; (ii) Agencia Estatal de Investigación (AEI), Ministry of Science and Innovation (MICIN), Spain, cofounded by FEDER funds/Development Fund—a way to build Europe, grant numbers #RTI2018-094079-B-100, #RTC2019-007125-1, to I.F.; #PID2019-108651RJ-I00, PID2022-141984OB-I00 and RYC2021-034121-I, to J.V. J.V. was funded by AEI, MICIN, through the Retos Investigación grant number PID2019-108651RJ-I00/DOI 10.13039/501100011033 and “Ramon y Cajal” program RYC2021-034121-I. The CIBEREHD, National Biomedical Research Institute on Liver and Gastrointestinal Diseases, is funded by the Instituto de Salud Carlos III, Spain. We thank the CERCA Programme/Generalitat de Catalunya for institutional support. Institutional support to CNAG was provided by the Spanish Ministry of Science and Innovation through the Instituto de Salud Carlos III, and by the Generalitat de Catalunya through the Departament de Salut and the Departament de Recerca i Universitats. C.C. is supported by Inserm, Université de Rennes, Ligue Contre le Cancer (R23037NN), INCa (EU TRANSCAN23-002-2023-129, INCa_18688, R21251ND), ITMO Cancer of AVIESAN within the framework of the 2021-2030 Cancer Control Strategy, on funds administered by Inserm (C18007NS, C20013NS, C20014NS), the French Ministry of Health and the French National Cancer Institute (PRT-K20-136). T.V.T. was supported by grants from the Spanish Ministry of Science, Innovation and University (PID2019-108008RJ-I00, PID2023-146827OB-I00), Fundació La Marató TV3 (201931-31), and “Ramon y Cajal” program (RYC2020-029098-I). L.F. received financial support from the “Ligue contre le cancer” (RS24/75-62) and from ITMO Cancer of Aviesan on funds administered by Inserm (C21044DS/ ASC21044DSA). S.A. is supported by PID2021-124694OA-I00, MCIN/AEI/ 10.13039/501100011033 and FEDER Una manera de hacer Europa, The European Union grant agreement 101077312* and Ramon y Cajal program RYC2022-036321-I. *, Peer reviewed
Docta Complutense
Publicación Artículo científico (JournalArticle)

Clathrin switches transforming growth factor-β role to pro-tumorigenic in liver cancer

  • Caballero-Díaz, Daniel
  • Bertran, Esther
  • Peñuelas-Haro, Irene
  • Moreno-Càceres, Joaquim
  • Malfettone, Andrea
  • López-Luque, Judit
  • Addante, Annalisa
  • Herrera González, Blanca María
  • Sánchez Muñoz, Aranzazu
  • Alay, Ania
  • Solé, Xavier
  • Serrano, Teresa
  • Ramos, Emilio
  • Fabregat Romero, María Isabel
Background & Aims: Upon ligand binding, tyrosine kinase receptors, such as epidermal growth factor receptor (EGFR), are recruited into clathrin-coated pits for internalization by endocytosis, which is relevant for signalling and/or receptor degradation. In liver cells, transforming growth factor-b (TGFb) induces both pro- and anti-apoptotic signals; the latter are mediated by the EGFR pathway. Since EGFR mainly traffics via clathrin-coated vesicles, we aimed to analyse the potential role of clathrin in TGF-b-induced signalling in liver cells and its relevance in liver cancer. Methods: Real-Time PCR and immunohistochemistry were used to analyse clathrin heavy-chain expression in human (CLTC) and mice (Cltc) liver tumours. Transient knockdown (siRNA) or overexpression of CLTC were used to analyse its role on TGF-b and EGFR signalling in vitro. Bioinformatic analysis was used to determine the effect of CLTC and TGFB1 expression on prognosis and overall survival in patients with hepatocellular carcinoma (HCC). Results: Clathrin expression increased during liver tumorigenesis in humans and mice. CLTC knockdown cells responded to TGF-b phosphorylating SMADs (canonical signalling) but showed impairment in the anti-apoptotic signals (EGFR transactivation). Experiments of loss or gain of function in HCC cells reveal an essential role for clathrin in inhibiting TGF-b-induced apoptosis and upregulation of its pro-apoptotic target NOX4. Autocrine TGF-b signalling in invasive HCC cells upregulates CLTC expression, switching its role to pro-tumorigenic. A positive correlation between TGFB1 and CLTC was found in HCC cells and patients. Patients expressing high levels of TGFB1 and CLTC had a worse prognosis and lower overall survival. Conclusions: This work describes a novel role for clathrin in liver tumorigenesis, favouring non-canonical pro-tumorigenic TGF-b pathways. CLTC expression in human HCC samples could help select patients that would benefit from TGF-b-targeted therapy. Lay summary: Clathrin heavy-chain expression increases during liver tumorigenesis in humans (CLTC) and mice (Cltc), altering the cellular response to TGF-b in favour of anti-apoptotic/ pro-tumorigenic signals. A positive correlation between TGFB1 and CLTC was found in HCC cells and patients. Patients expressing high levels of TGFB1 and CLTC had a worse prognosis and lower overall survival. CLTC expression in HCC human samples could help select patients that would benefit from therapies targeting TGF-b.